HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Day, B. N. Articles by Lasley, J. F. Search for Related Content PubMed PubMed Citation Articles by Day, B. N. Articles by Lasley, J. F.

Fertility of Swine following Superovulation^{1, 2,}

Missouri Agricultural Experiment Station, Columbia

Abstract

Data on estrous behavior, ovulation rate and fertility are presented for 239 gilts and sows in experiments designed to determine the reproductive performance following the injection of gonadotrophins to induce superovulation.

An increased incidence of ovulation without sexual receptivity occurred in animals injected on the 17th or 18th day of the estrous cycle with pituitary FSH, a combined treatment of PMS and HCG, or PMS alone. Ovulation rate was not significantly increased in animals treated with pituitary FSH; however, superovulation was induced by the injection of 1,200 I.U. of PMS on day 17 of the cycle and 500 I.U. HCG on day 20. Average litter size at 25 days after mating was consistently higher in four treatment groups receiving PMS, but the mean differences from appropriate control animals were not statistically significant. The standard deviation of ovulation rate and of litter size at 25 days was markedly increased in animals receiving PMS. Litter size at 25 days of pregnancy in superovulated gilts ranged from 4 to 26 live pigs.

¹ Contribution from Missouri Agricultural Experiment Station. Journal Series Number 5004. Approved by Director.

² This investigation was supported in part by U.S.P.H.S. Grant HD-01170 from National Institutes of Health. The authors gratefully acknowledge that the gonadotrophin preparations were made available by the Upjohn Company, Kalamazoo, Michigan; Armour Pharmaceutical Company, Kankakee, Illinois and Haver-Lockhart Laboratories, Kansas City, Missouri.